Feminism, Civil Rights, and Social Policy in the 1990s
Levenstein, Lisa
The University of North Carolina at Greensboro
2020
186
Ph.D.
The University of North Carolina at Greensboro
2020
In December 1990, the U.S. Food and Drug Administration (FDA) approved Norplant, the first subdermal implantable contraceptive device ever manufactured. Norplant consisted of six thin, silicone rubber rods that were surgically inserted under the skin of a woman's arm, slowly releasing hormones to prevent pregnancies for up to five years. Many people in the United States celebrated its approval, including some feminists and doctors. They believed new contraceptive research would afford women greater reproductive control and additional freedoms. But feminists in Bangladesh, Brazil, and Egypt had been claiming that the drug's testing trials were unethical, and that Norplant was unsafe. They warned U.S. activists about these dangers and within months, their predictions came to fruition. Judges, lawmakers, and community leaders pressured poor and minority women to use Norplant and many claimed they experienced terrible side effects from the drug. After U.S. women's health activists mobilized on patients' behalf, class action lawyers took notice and filed 200 lawsuits against Norplant's manufacturer on behalf of fifty thousand women. Just twelve years after its FDA approval, Norplant was removed from the American market. This dissertation investigates the many historical constructions that defined Norplant from its development in the 1960s to its downfall.